Safety and Tolerability of Lactobacillus reuteri DSM 17938 and Effects on Biomarkers in Healthy Adults: Results from a Randomized Masked Trial

Abstract

BackgroundThere are few carefully-designed studies investigating the safety of individual probiotics approved under Investigational New Drug policies.ObjectivesThe primary aim of this prospective, double-blind placebo-controlled trial was to investigate if daily treatment of adults with Lactobacillus reuteri DSM 17938 (LR) for 2 months is safe and well-tolerated. Our secondary aim was to determine if LR treatment has immune effects as determined by regulatory T cell percentages, expression of toll-like receptors (TLR)-2 and −4 on circulating peripheral blood mononuclear cells (PMBCs), cytokine expression by stimulated PBMC, and intestinal inflammation as measured by fecal calprotectin.MethodsForty healthy adults were randomized to a daily dose of 5×108 CFUs of LR (n = 30) or placebo (n = 10) for 2 months. Participants completed a daily diary card and had 7 clinic visits during treatment and observation.ResultsThere were no severe adverse events (SAEs) and no significant differences in adverse events (AEs). There were no differences in PBMC subclasses, TLRs, or cytokine expression after treatment. The probiotic-treated group had a significantly higher fecal calprotectin level than the placebo group after 2 months of treatment: 50 µg/g (IQR 24–127 µg/g) vs. 17 µg/g (IQR 11–26 µg/g), p = 0.03, although values remained in the normal clinical range (0–162.9 µg/g). LR vials retained >108 CFUs viable organisms/ml.ConclusionsLR is safe and well tolerated in adults, without significant changes in immunologic markers. There was a small but significant increase in fecal calprotectin, perhaps indicating some element of immune recognition at the intestinal level.Trial RegistrationClinical Trials.gov NCT00922727

Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis

“…The probiotic was associated with a significantly higher rate of diarrhea that was indeed self-limiting and not associated with any changes in stool WBC. The incidence of diarrhea with probiotics has varied in prior studies in cirrhotic and non-cirrhotic patients but it appears to be non-infectious or non-inflammatory in origin and could represent the entry of the large batch of these microbes into the colonic microbiome 8, 29 . Infections were similarly distributed among groups and were not related to LGG.…”

Effects of Supplementation of the Synbiotic Ecologic® 825/FOS P6 on Intestinal Barrier Function in Healthy Humans: A Randomized Controlled Trial

“…In contrast, no differences in cytokine expression were found in a double-blind, placebo-controlled study after two months of L . reuteri supplementation [32]. Also six weeks Bacteroides xylanisolvents supplementation did not affect inflammatory markers IL-6, interferon-γ and C-reactive protein levels [33].…”

Benefits of probiotics on enteral nutrition in preterm neonates: a systematic review

“…Strains with a documented ability to stimulate gut motility and gastric emptying and reduce the incidence and severity of NEC such as L. reuteri DSM 17938 may be suitable for such trials (11,(80)(81)(82)(83)(84). For example, future RCTs could compare probiotics with L. reuteri DSM 17938 with probiotics without L. reuteri DSM 17938.…”